Lv11
10 积分 2024-06-11 加入
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
5小时前
待确认
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
17天前
已完结
Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity
18天前
已完结
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
18天前
已完结
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial
20天前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
22天前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
22天前
已完结
Mechanisms of weight regain
29天前
已完结
GLP-1 receptor agonists
1个月前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
1个月前
已完结
皖公网安备34019202002308
